Abstract Search

ea0099rc5.2 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

Lanreotide in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): A randomised, double-blind, placebo-controlled trial

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M. , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Weterings Annick J. , Vink Juan M. , Tanck Michael W.T. . , Fliers Eric , Bisschop Peter H.

Background: Patients with non-functioning pituitary macroadenoma (NFMA) currently have no established medical treatment options. Somatostatin analogues may decrease tumour size, but randomised controlled trials are lacking. In vivo somatostatin receptor assessment with 68Ga-DOTATATE PET could help in selecting patients for treatment. We aimed to determine the effect of the somatostatin analogue lanreotide on tumour size in patients with a 68Ga-DOTATATE PE...

0 shares

Endocrine Abstracts

Lanreotide in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): A randomised, double-blind, placebo-controlled trial

BiosciAbstracts